Tag: Clinical trial

Nature Medicine, Published online: 30 June 2026; doi:10.1038/s41591-026-04449-9

In the phase 1 ReMIND trial of tumor-associated antigen-specific T cells in patients with pediatric central nervous system tumors, treatment was generally well tolerated with one complete response and three long-term responders.

Nature Medicine, Published online: 29 June 2026; doi:10.1038/s41591-026-04544-x

Author Correction: SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial

Nature Medicine, Published online: 26 June 2026; doi:10.1038/s41591-026-04505-4

As part of a clinical trial, re-administration of AAV gene therapy in four patients with congenital deafness, who had previously received a first gene therapy dose and developed neutralizing antibodies, was safe and led to further hearing improvements.

Nature Medicine, Published online: 26 June 2026; doi:10.1038/s41591-026-04503-6

A pragmatic cluster-randomized trial found that ChatGPT-4o-assisted decision support in Kenyan primary care facilities did not significantly reduce 14-day treatment failure over usual care.

Nature Medicine, Published online: 25 June 2026; doi:10.1038/s41591-026-04453-z

In the randomized phase 2 Neo-CheckRay trial, patients with early-stage ER+HER2− breast cancer received neoadjuvant immune-modulating stereotactic body radiation therapy with or without durvalumab, and with or without the anti-CD73 antibody oleclumab, leading to encouraging clinical responses when durvalumab was added including in patients with PD-L1-negative tumors.

Nature Medicine, Published online: 25 June 2026; doi:10.1038/s41591-026-04471-x

In the ongoing phase 2 GMMG-HD10/DSMM-XX (MajesTEC-5) trial in patients with transplant-eligible, newly diagnosed multiple myeloma, induction with the BCMA×CD3 bispecific engager teclistamab in combination with daratumumab plus lenalidomide, with or without bortezomib, had a similar toxicity profile to other bispecific regimens with an encouraging and deep response rate.

Nature Medicine, Published online: 24 June 2026; doi:10.1038/s41591-026-04508-1

Retraction Note: Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial